HEREDITARY ANGIOEDEMA - TYPE 1
Clinical trials for HEREDITARY ANGIOEDEMA - TYPE 1 explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA - TYPE 1 trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA - TYPE 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Silencing the swelling: new drug aims to stop HAE attacks
Disease control Recruiting nowThis study tests a new medicine called ADX-324 for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The drug uses a technology called siRNA to lower a protein involved in triggering attacks. About 90 adults with HAE type 1 or 2 wi…
Matched conditions: HEREDITARY ANGIOEDEMA - TYPE 1
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:54 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who finished a previous phase 3 trial of ADX-324. It aims to see if the drug is safe and can prevent swelling attacks over a longer period. About 90 participants will receive additional doses of ADX-324 and be monitored fo…
Matched conditions: HEREDITARY ANGIOEDEMA - TYPE 1
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Smartphone diaries reveal hidden toll of rare swelling disease
Knowledge-focused Recruiting nowThis study tracks 30 adults with hereditary angioedema (HAE) using daily smartphone surveys for 8 weeks. The goal is to capture the real-time emotional, social, and physical burden of the disease, which may be missed by standard questionnaires. Participants answer questions about…
Matched conditions: HEREDITARY ANGIOEDEMA - TYPE 1
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Knowledge-focused
Last updated May 11, 2026 20:38 UTC